{
  "schema_version": "1.0",
  "source": "regulatory",
  "data_as_of": "2026-09-09T03:02:20.926Z",
  "selected_count": 20,
  "sampled": true,
  "records": [
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_tlx_2026-09-11",
      "title": "Telix Pharmaceuticals Limited: TLX101-Px",
      "summary": "Recurrent or progressive glioma (brain cancer)",
      "published_date": "2026-09-11",
      "url": "https://www.pdufa.bio/pdufa/TLX",
      "metadata": {
        "stream": "pdufa",
        "ticker": "TLX",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": {
          "nct": "NCT07100730",
          "status": "recruiting",
          "ongoing": true,
          "pcd": "2027-07",
          "pcd_type": "estimated",
          "updated": "2026-04-16",
          "slip": null
        },
        "days_to_decision": 2
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_srrk_2026-09-30",
      "title": "Scholar Rock Holding Corporation: Apitegromab - (SAPPHIRE)",
      "summary": "Spinal muscular atrophy (SMA), children and adults (BLA)",
      "published_date": "2026-09-30",
      "url": "https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-fda-review-apitegromab-biologics-license",
      "metadata": {
        "stream": "pdufa",
        "ticker": "SRRK",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 21
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_rhhby_2026-10-09",
      "title": "Roche Holding AG: Tecentriq (atezolizumab) adjuvant - (stage III colon)",
      "summary": "Adjuvant stage III dMMR/MSI-H colon cancer",
      "published_date": "2026-10-09",
      "url": "https://www.pdufa.bio/pdufa/RHHBY",
      "metadata": {
        "stream": "pdufa",
        "ticker": "RHHBY",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 30
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_rare_2026-09-19",
      "title": "Ultragenyx Pharmaceutical Inc.: UX111 - (ABO-102)",
      "summary": "Sanfilippo syndrome type A (MPS IIIA)",
      "published_date": "2026-09-19",
      "url": "https://www.pdufa.bio/pdufa/RARE",
      "metadata": {
        "stream": "pdufa",
        "ticker": "RARE",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": {
          "nct": "NCT03517085",
          "status": "completed",
          "ongoing": false,
          "pcd": "2021-11-02",
          "pcd_type": "actual",
          "updated": "2022-11-18",
          "slip": null
        },
        "days_to_decision": 10
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_nvo_mim8_2026-09-30",
      "title": "Novo Nordisk A/S: Mim8 (denecimig)",
      "summary": "Hemophilia A prophylaxis, with or without inhibitors",
      "published_date": "2026-09-30",
      "url": "https://www.pdufa.bio/pdufa/NVO-mim8",
      "metadata": {
        "stream": "pdufa",
        "ticker": "NVO",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 21
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_mrk_2026-10-10",
      "title": "Merck: Ifinatamab deruxtecan (I-DXd)",
      "summary": "Extensive-stage small cell lung cancer",
      "published_date": "2026-10-10",
      "url": "https://www.pdufa.bio/pdufa/MRK",
      "metadata": {
        "stream": "pdufa",
        "ticker": "MRK",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": {
          "nct": "NCT04700124",
          "status": "completed",
          "ongoing": false,
          "pcd": "2025-10-27",
          "pcd_type": "actual",
          "updated": "2026-02-05",
          "slip": null
        },
        "days_to_decision": 31
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_mrk_2026-09-21",
      "title": "Merck & Co., Inc.: WINREVAIR (sotatercept-csrk) - (HYPERION)",
      "summary": "Recently diagnosed pulmonary arterial hypertension (label update)",
      "published_date": "2026-09-21",
      "url": "https://www.pdufa.bio/pdufa/MRK",
      "metadata": {
        "stream": "pdufa",
        "ticker": "MRK",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 12
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_mirm_2026-09-26",
      "title": "Mirum Pharmaceuticals, Inc.: zilurgisertib",
      "summary": "",
      "published_date": "2026-09-26",
      "url": "https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm",
      "metadata": {
        "stream": "pdufa",
        "ticker": "MIRM",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 17
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_incy_2026-09-26",
      "title": "INCYTE CORP: zilurgisertib",
      "summary": "",
      "published_date": "2026-09-26",
      "url": "https://www.pdufa.bio/pdufa/INCY",
      "metadata": {
        "stream": "pdufa",
        "ticker": "INCY",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": null,
        "days_to_decision": 17
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "pdufa:pdufa_bfri_2026-09-28",
      "title": "Biofrontera Inc.: Ameluz (aminolevulinic acid hydrochloride) topical gel in combination with the RhodoLED red-light lamp series",
      "summary": "Basal cell carcinoma",
      "published_date": "2026-09-28",
      "url": "https://www.pdufa.bio/pdufa/BFRI",
      "metadata": {
        "stream": "pdufa",
        "ticker": "BFRI",
        "type": "PDUFA",
        "status": "Upcoming",
        "nct_id": {
          "nct": "NCT02144077",
          "status": "completed",
          "ongoing": false,
          "pcd": "2015-11-17",
          "pcd_type": "actual",
          "updated": "2022-11-03",
          "slip": null
        },
        "days_to_decision": 19
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:NDA018052:32",
      "title": "NDA018052: GYNE-LOTRIMIN",
      "summary": "AP",
      "published_date": "20100412",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018052",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "NDA018052",
        "sponsor": "BAYER HEALTHCARE LLC",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "32",
          "submission_status": "AP",
          "submission_status_date": "20100412",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "814",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/018052s032ltr.pdf",
              "date": "20100414",
              "type": "Letter"
            },
            {
              "id": "33406",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018052Orig1s032lbl.pdf",
              "date": "20150112",
              "type": "Label"
            }
          ]
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:NDA018012:31",
      "title": "NDA018012: PAMELOR",
      "summary": "AP",
      "published_date": "20140728",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018012",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "NDA018012",
        "sponsor": "SPECGX LLC",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "31",
          "submission_status": "AP",
          "submission_status_date": "20140728",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "13976",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/018012Orig1s031,018013Orig1s063,017090Orig1s078,019906Orig1s039ltr.pdf",
              "date": "20140729",
              "type": "Letter"
            },
            {
              "id": "33391",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018012s031lbl.pdf",
              "date": "20140729",
              "type": "Label"
            }
          ]
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA080807:34",
      "title": "ANDA080807: DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE",
      "summary": "AP",
      "published_date": "19891018",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080807",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA080807",
        "sponsor": "IMPAX LABS",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "34",
          "submission_status": "AP",
          "submission_status_date": "19891018",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA080301:record",
      "title": "ANDA080301: PREDNISONE",
      "summary": "Drugs@FDA application record",
      "published_date": null,
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080301",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA080301",
        "sponsor": "MARSHALL PHARMA",
        "submission": {}
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA077850:3",
      "title": "ANDA077850: NICOTINE POLACRILEX",
      "summary": "AP",
      "published_date": "20130919",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077850",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA077850",
        "sponsor": "IVAX SUB TEVA PHARMS",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "3",
          "submission_status": "AP",
          "submission_status_date": "20130919",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA077551:7",
      "title": "ANDA077551: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE",
      "summary": "AP",
      "published_date": "20150120",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077551",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA077551",
        "sponsor": "SANDOZ",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "7",
          "submission_status": "AP",
          "submission_status_date": "20150120",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA077248:1",
      "title": "ANDA077248: PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE",
      "summary": "AP",
      "published_date": "20060331",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077248",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA077248",
        "sponsor": "IMPAX LABS",
        "submission": {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20060331"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA076955:1",
      "title": "ANDA076955: FLUMAZENIL, FLUMAZENIL",
      "summary": "AP",
      "published_date": "20041012",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076955",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA076955",
        "sponsor": "FRESENIUS KABI USA",
        "submission": {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20041012"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA076673:2",
      "title": "ANDA076673: CIPROFLOXACIN HYDROCHLORIDE",
      "summary": "AP",
      "published_date": "20070420",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076673",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA076673",
        "sponsor": "WATSON LABS INC",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "2",
          "submission_status": "AP",
          "submission_status_date": "20070420",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    },
    {
      "source": "regulatory",
      "source_id": "drugsfda:ANDA076392:9",
      "title": "ANDA076392: MEFLOQUINE HYDROCHLORIDE",
      "summary": "AP",
      "published_date": "20161011",
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076392",
      "metadata": {
        "stream": "drugsfda",
        "application_number": "ANDA076392",
        "sponsor": "BARR",
        "submission": {
          "submission_type": "SUPPL",
          "submission_number": "9",
          "submission_status": "AP",
          "submission_status_date": "20161011",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling"
        }
      },
      "fetched_at": "2026-09-09T03:02:20.926Z"
    }
  ],
  "next_cursor": null
}